🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 657.76 -0.6% NASDAQ 100: 590.38 -0.8% Dow Jones: 459.51 -0.8%

Joel Greenblatt’s PTGX Holdings & Trades

First Buy
Q2 2021
Duration Held
6 Quarters
Largest Add
Q1 2025
+23,072 Shares
Current Position
21,595 Shares
$1.89 M Value

Joel Greenblatt's PTGX Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 21,595 shares of Protagonist Therapeutics, Inc. (PTGX) worth $1.89 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this short-term holding has been held for 6 quarters.

Based on 13F filings, Joel Greenblatt has maintained this position in PTGX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2025, adding 23,072 shares. Largest reduction occurred in Q3 2025, reducing 15,089 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Protagonist Therapeutics (PTGX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Protagonist Therapeutics (PTGX) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -603 Reduce 2.72% 21,595 $87.34
Q3 2025 -15,089 Reduce 40.47% 22,198 $66.43
Q2 2025 +14,215 Add 61.61% 37,287 $55.26
Q1 2025 +23,072 New Buy 23,072 $48.36
Q3 2021 -4,793 Sold Out 0 $0.00
Q2 2021 +4,793 New Buy 4,793 $44.86

Joel Greenblatt's Protagonist Therapeutics Investment FAQs

Joel Greenblatt first purchased Protagonist Therapeutics, Inc. (PTGX) in Q2 2021, acquiring 4,793 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Protagonist Therapeutics, Inc. (PTGX) for 6 quarters since Q2 2021.

Joel Greenblatt's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q1 2025, adding 23,072 shares worth $1.12 M.

According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 21,595 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $1.89 M.

As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 37,287 shares, as reported at the end of Q2 2025.